Tesaro, an oncology-focused biopharmaceutical company, and Janssen Biotech have formed a global collaboration and license agreement focused on the development and commercialization of niraparib specifically for the treatment of prostate cancer. Niraparib is an oral, once daily, potent, and highly selective PARP inhibitor that is currently being evaluated in Phase 3 clinical trials for ovarian and breast cancer. “We are pleased to be working with Janssen, a leader in the prostate cancer field,...